Gabelli & Co Investment Advisers’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.16K	Hold	38,150	–	–	﹤0.01%	314
2026 Q1	$774	Hold	38,150	–	–	﹤0.01%	296
2025 Q4	$992	Hold	38,150	–	–	﹤0.01%	277
2025 Q3	$1.34K	Hold	38,150	–	–	﹤0.01%	270
2025 Q2	$1.56K	Hold	38,150	–	–	﹤0.01%	258
2025 Q1	$2.92K	Buy	+38,150	New	+$2.32K	﹤0.01%	239
2024 Q4	–	Sell	-38,150	Closed	-$1.21K	–	266
2024 Q3	$1.21K	Buy	+38,150	New	+$2.21K	﹤0.01%	212

Other funds holding SLXNW

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Gabelli & Co Investment Advisers's SLXNW Position: Q2 2026 in Review

Gabelli & Co Investment Advisers held its Silexion Therapeutics Warrant (SLXNW) position steady in Q2 2026 at 38,150 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #314.

Gabelli & Co Investment Advisers first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.92K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

Gabelli & Co Investment Advisers held 38,150 shares of Silexion Therapeutics Warrant worth $1.16K as of Q2 2026.
Gabelli & Co Investment Advisers left its Silexion Therapeutics Warrant share count unchanged in Q2 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Gabelli & Co Investment Advisers's portfolio in Q2 2026, its #314 holding.
Gabelli & Co Investment Advisers first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Gabelli & Co Investment Advisers's Silexion Therapeutics Warrant position peaked at $2.92K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.